Argitalpenak (110) MIGUEL PAYA PERIS argitalpenak

2019

  1. Defective induction of COX-2 expression by psoriatic fibroblasts promotes pro-inflammatory activation of macrophages

    Frontiers in Immunology, Vol. 10, Núm. MAR

2017

  1. Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis

    Journal of Investigative Dermatology, Vol. 137, Núm. 1, pp. 123-131

2016

  1. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease

    Molecular Neurobiology, Vol. 53, Núm. 2, pp. 1296-1309

2013

  1. NF-κB and STAT3 inhibition as a therapeutic strategy in psoriasis: In vitro and in vivo effects of BTH

    Journal of Investigative Dermatology, Vol. 133, Núm. 10, pp. 2362-2371

  2. Potential antipsoriatic effect of chondroitin sulfate through inhibition of NF-κB and STAT3 in human keratinocytes

    Pharmacological Research, Vol. 70, Núm. 1, pp. 20-26

2011

  1. Papel de la activacion de NF-KB y de la produccion de TNFá en queratinocitos primarios humanos estimulados con TPA: XXXII Congreso Nacional de la SEF: póster premiado

    Actualidad en farmacología y terapéutica, Vol. 9, Núm. 2, pp. 144-146

  2. Perthamides C-F, potent human antipsoriatic cyclopeptides

    Tetrahedron, Vol. 67, Núm. 40, pp. 7780-7786

2010

  1. Anthrax lethal toxin down-regulates type-IIA secreted phospholipase A2 expression through MAPK/NF-κB inactivation

    Biochemical Pharmacology, Vol. 79, Núm. 8, pp. 1149-1155

  2. Toward the discovery of new agents able to inhibit the expression of microsomal prostaglandin e synthase-1 enzyme as promising tools in drug development

    Chemical Biology and Drug Design, Vol. 76, Núm. 1, pp. 17-24

  3. Type-IIA secreted phospholipase A2 is an endogenous antibiotic-like protein of the host

    Biochimie, Vol. 92, Núm. 6, pp. 583-587

2009

  1. Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression

    European Journal of Pharmacology, Vol. 620, Núm. 1-3, pp. 112-119

  2. Coscinolactams A and B: new nitrogen-containing sesterterpenoids from the marine sponge Coscinoderma mathewsi exerting anti-inflammatory properties

    Tetrahedron, Vol. 65, Núm. 15, pp. 2905-2909

2008

  1. Avarol inhibits TNF-α generation and NF-κB activation in human cells and in animal models

    Life Sciences, Vol. 82, Núm. 5-6, pp. 256-264

  2. Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the γ-hydroxybutenolide scaffold

    Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 19, pp. 9056-9064

2007

  1. Antipsoriatic effects of avarol-3′-thiosalicylate are mediated by inhibition of TNF-α generation and NF-αB activation in mouse skin

    British Journal of Pharmacology, Vol. 152, Núm. 3, pp. 353-365

  2. Synthesis and evaluation of diverse thio avarol derivatives as potential UVB photoprotective candidates

    Bioorganic and Medicinal Chemistry Letters, Vol. 17, Núm. 9, pp. 2561-2565

  3. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the γ-hydroxybutenolide scaffold: A new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression

    Journal of Medicinal Chemistry, Vol. 50, Núm. 9, pp. 2176-2184

2006

  1. Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation

    Life Sciences, Vol. 79, Núm. 25, pp. 2395-2404

  2. Marine sponge metabolites for the control of inflammatory diseases

    Current Opinion in Investigational Drugs, Vol. 7, Núm. 11, pp. 974-979

2005

  1. Búsqueda y evaluación de nuevos agentes naturales con actividad antiinflamatoria y antiartrítica

    Revista de fitoterapia, Vol. 5, Núm. 1, pp. 82